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Nonalcoholic steatohepatitis (NASH)—the severe 
histological form of nonalcoholic fatty liver disease 
(NAFLD)—is regarded as a major health problem 
worldwide (1,2). The disease can progress to liver cirrhosis 
and eventually to hepatocellular carcinoma (1,3). Treatment 
of NASH and NASH-fibrosis is thus increasingly being 
given priority in the clinical field. Yet, these efforts face 
challenges not only related to the design and validation 
of novel pharmacological agents, but also to the need to 
optimize treatment options as well as improve access to 
therapies. In fact, while many drugs are currently being 
tested for safety and efficacy, only a few approved options 
for the treatment of NASH presently exist (4,5). It is thus 
expected that, in the near future, emphasis will be given to 
selecting the right drug for treating NASH patients from a 
wide spectrum of treatment choices. Hence, identification 
of early predictors of treatment response represents an 
unmet and relevant need. 
Loomba and coworkers have recently published results 
yielded by a post-hoc analysis of clinical predictors of 
histologic response (6), whereby the data was sourced from 
the FLINT trial—a double-blind, placebo-controlled, 
randomized clinical trial conducted at multiple medical 
centers across the U.S. involving non-cirrhotic NASH 
patients—to assess the treatment efficacy of obeticholic 
acid (OCA, a farnesoid X receptor agonist) given orally 
(25 mg daily) for 72 weeks (7). Specifically, the authors 
aimed at identifying baseline and early on-treatment 
factors that might predict histologic response. By utilizing 
a multivariable-adjusted model, the authors found that 
baseline NAS (NASH activity score) >5, baseline triglyceride 
levels ≤154 mg/dL, baseline international normalized 
ratio ≤1, baseline aspartate aminotransferase (AST) level 
≤49 IU/L, and a decrease in alanine aminotransferase (ALT) 
levels at week 24 by at least 17 IU/L were significantly 
associated with histological improvement (6). These 
interesting and promising findings deserve some reflections. 
What is the biological meaning of these findings?
Notably, all predictors in the model with the exception 
of the NAS score are indeed biochemical measurements 
that include liver enzymes, specifically aminotransferases, 
and circulating levels of triglycerides. One might argue 
that liver enzymes are expected predictors of treatment 
response because ALT and AST have been widely used 
in prior studies not only as surrogate biomarkers of liver 
disease severity (8,9) but also to monitor response to 
any liver disease, particularly the treatment of chronic 
viral hepatitis. Nevertheless, more recent data indicate 
that serum concentrations aminotransferases are linked 
to cardiovascular disease and the metabolic syndrome 
(9-11). Therefore, it has been postulated that elevated 
aminotransferase values approaching the upper-normal 
threshold reflect high levels of hepatic transamination 
in response to increased NAFLD-associated metabolic 
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demands (9,11). In fact, we have evaluated the expression 
levels of aminotransferases in the liver of patients 
with NAFLD and have explored their relationship 
with global metabolic changes in the circulation (11). 
Profiling of circulating metabolites indicated that serum 
aminotransferase concentrations are a signature of liver 
metabolic perturbations, particularly at the amino acid 
metabolism and Krebs cycle level (11). Robust confirmation 
of that finding can be found in the representation of 
GPT and GOT—including their isoenzymes—in the 
global metabolic map (Figure 1). The pathways in which 
aminotransferases are involved cover not only an extensive 
portion of the carbohydrate and amino acid metabolism, but 
energy metabolism as well (Figure 1). The role of GOT1 
[aspartate aminotransferase, cytoplasmic (EC:2.6.1.1)] 
is particularly interesting, as it presents 8 direct hits and 
256 indirect hits in the global metabolic map (Figure 1). 
Consequently, it is plausible to suggest that baseline levels 
of AST—as reported by Loomba and coworkers (6)—
are not necessarily prognostic indicators of histological 
improvement but also dynamic biosensors of the patients’ 
metabolic status. 
Figure 1 Aminotransferases as biosensors of metabolism. Metabolic map showing the complexity of the pathways and enzyme-related 
modules associated with aminotransferases (GPT1, GPT2, GOT1 and GOT2). Figure also shows primary and secondary bile acid 
biosynthesis in the right section of the map; bile acid biosynthesis has been highlighted because OCA is a regulator of bile in the liver. OCA 
is conjugated with glycine or taurine in the liver and secreted into bile; these conjugates of OCA are absorbed in the small intestine leading 
to enterohepatic recirculation. Metabolic map was done by iPath3.0 in the web interface available at: https://pathways.embl.de/. Input data 
for map construction: map00120, map00250, K14455, K14454, map00471, K00814, map00121, 1.14.14.23; pathways and enzyme modules 
are highlighted in red. Detailed information on pathways can be found in the KEGG database (https://www.genome.jp/kegg/kegg2.html), 
including KEGG pathways maps (KEGG Pathways), reactions and reaction classes (KEGG reactions) and KEGG modules. Glutamic-
Pyruvate Transaminase (alanine aminotransferase); Glutamic-Oxaloacetic Transaminase (aspartate aminotransferase). OCA, obeticholic acid.
Aminotransferases as biosensors of metabolism
K14454: GOT1; aspartate aminotransferase, cytoplasmic [EC:2.6.1.1]
K14455: GOT2; aspartate aminotransferase, mitochondrial [EC:2.6.1.1]
map00250: Alanine, aspartate and glutamate metabolism
map00471: D-Glutamine and D-glutamate metabolism
K00814: GPT, ALT; alanine transaminase [EC:2.6.1.2]
map00120: Primary bile acid biosynthesis
map00121: Secondary bile acid biosynthesis
1.14.14.23: CYP7A1 (cholesterol 7-alpha-
hydroxylase)
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Clinical predictors versus genetic predictors of 
treatment response
Another important issue to discuss is the potentiality for 
including other factors, such as genetic predictors, in the 
model. This hypothesis could be tested, for example, via a 
genome-wide exploration of variants (GWAS), by necessity 
in a large cohort. Another, more feasible, alternative 
could be a rational selection of gene candidates based 
on biological modeling. We explored the connectivity 
network around NR1H4 (FXR) and aminotransferase 
genes (GPT1, GPT2, GOT1, and GOT2) and found 
some potential candidates for inclusion into the model, 
including CYP7A1 (cytochrome P450 family 7 subfamily A 
member 1) (Figure 2A). This finding is not unexpected, as 
FXR not only regulates bile acid biosynthesis controlling 
CYP7A1 transcription through the FGFR4-JNK-HNF4α 
pathway, but also hepatic gluconeogenesis, glycolisis and 
lipogenesis, including triglyceride biosynthesis through the 
SHP (the inhibitory nuclear receptor small heterodimer 
partner)-SREBP-1c pathway (12). This complex molecular 
interaction of the drug target may explain some adverse 
effects of OCA on insulin resistance (7), prompting the 
question of how the incorporation of plasma glucose-related 
variables may affect the predictive model results reported 
by Loomba et al. (6). As a proof of principle, it can be 
shown that variants in, or in close proximity to, CYP7A1 are 
associated with lipid traits in the UK Biobank (Figure 2B), 
which reinforces the concept that baseline levels of lipids 
in patients with NASH that responded or not to OCA 
are genetically modulated. In addition, text mining would 
suggest that GPT (ALT) could be a central node in 
connecting the sub-network of nuclear receptors with the 
one composed by aminotransferases and enzymes of the 
glutamic acid metabolism, as GPT and FXR might be co-
expressed in some species (Figure 2B). 
A final question that still remains unanswered pertains to 
the generalizability of Loomba et al.’s work (6). Specifically, 
one may wonder whether the reported findings can be 
extended to all populations and to all kinds of anti-NASH 
drugs. Finally, as FXR and CYP7A1 are at the core of 
the metabolism of bile acids, it remains to be explored 
whether other environmental factors, such as diet or host 
“microbiotas”, may modulate the therapeutic response of 
any drug but OCA in particular, and vice versa (13).
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Figure 2 Protein interaction network of FXR (NR1H4). (A) The connectivity gene/protein interaction network shows a set of genes/
proteins (nodes) connected by edges representing functional relationships among them. Network shows input genes/proteins [NR1H4, also 
known as FXR, GPT1, GPT2, GOT1 and GOT2 and predicted genes/proteins (see below)]. The functional products of genes (proteins) 
interact with each other by different mechanisms; figure shows different level of evidence extracted from curated databases, experimentally 
determined, predicted, etc., as explained in the figure footnote. Connectivity network was generated in the STRING’s website (https://
string-db.org). Network depicts 25 nodes and 131 edges; enrichment P<1.0e-16. Pathways overrepresented are: map04919: thyroid hormone 
signaling pathway (P=9.11e-15); map00220: arginine biosynthesis (P=9.97e-12); map01200: carbon metabolism (P=2.63e-11); map00250: 
alanine, aspartate and glutamate metabolism (P=9.61e-11); map01210: 2-oxocarboxylic acid metabolism (P=9.48e-08). Predicted functional 
partners: CYP7A1 (cholesterol 7-alpha-monooxygenase; catalyzes a rate-limiting step in cholesterol catabolism and bile acid biosynthesis by 
introducing a hydrophilic moiety at position 7 of cholesterol). Important for cholesterol homeostasis; cytochrome P450 family 7 (504 aa); 
NCOA1 (nuclear receptor coactivator 1); involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), 
retinoids (RXRs), thyroid hormone (TRs) and prostanoids; MDH2 (malate dehydrogenase, mitochondrial); MDH1 (malate dehydrogenase, 
cytoplasmic); RXRA (retinoic acid receptor RXR-alpha; Receptor for retinoic acid and RXRB (retinoic acid receptor RXR-beta); MED1 
(mediator of RNA polymerase II transcription subunit 1); GLUD1 (glutamate dehydrogenase 1, mitochondrial); GLUD2 (glutamate 
dehydrogenase 2, mitochondrial); NR0B2 (nuclear receptor subfamily 0 group B member 2). Clustering was performed based on k-means 
clustering. NCBI taxonomy Id: 9606. (B) Manhattan plot of associations between variants in CYP7A1 or near CYP7A1-locus and lipid traits 
(E78: disorders of lipoprotein metabolism and other lipidaemias as stated in the UK Biobank database) from individuals of the UK Biobank. 
The associations have been computed using 452,264 UK Biobank White British individuals (http://geneatlas.roslin.ed.ac.uk/). Table shows 
effects (beta) of variants that reached genome wide-significance at a P<1e-8. MAF, minor allele frequency. 
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